Gastrointestinal biotech firm Salix Pharmaceuticals (NASDAQ:SLXP) announced Wednesday that the Food and Drug Administration has approved Fulyzaq, the company's orally taken diarrhea treatment for patients suffering from HIV or AIDS and on anti-retroviral therapy (ART).
Salix says it will begin marketing Fulyzaq early this year. The drug, which is the first gastrointestinal product of its kind, has patent protection up until at least 2018. Patients on anti-retroviral treatments to combat AIDS and HIV can contract diarrhea, and weight loss and other problems stemming from the condition can interfere with the treatment. The company estimates 150,000 to 180,000 people on anti-retroviral therapy suffer from non-infectious diarrhea, which would make them candidates for Fulyzaq.
Salix President and CEO Carolyn Logan explained the need Fulyzaq meets in the company's press release, saying, "Diarrhea negatively affects quality of life and is a common reason for discontinuing or switching ART regimen. Salix's expertise in gastrointestinal medicine should position the Company to deliver this much-needed treatment to HIV patients."
Shares of Salix jumped more than 5% during midday trading.
Dan Carroll has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Valeant Pharmaceuticals Int'l Inc.'s Shares Took Off Today
The serial pharmaceutical acquirer just closed its biggest deal to date.
Why Salix Pharmaceuticals, Ltd. Stock Was Clobbered in November
Salix Pharmaceuticals gets clobbered in November after the integrity of its management team is called into question following its third-quarter earnings results.
Why Salix Pharmaceuticals Ltd. Stock Was Throttled
Salix Pharmaceuticals is today's biggest loser after the company swung and missed badly on its third-quarter earnings results and fourth-quarter guidance.